Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 8—August 2019
Research

17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil

Ana Carolina Campi-AzevedoComments to Author , Vanessa Peruhype-Magalhāes, Jordana Grazziela Coelho-dos-Reis, Lis Ribeiro Antonelli, Christiane Costa-Pereira, Elaine Speziali, Laise Rodrigues Reis, Jandira Aparecida Lemos, José Geraldo Leite Ribeiro, Luiz Antônio Bastos Camacho, Maria de Lourdes de Sousa Maia, Sheila Maria Barbosa de Lima, Marisol Simões, Reinaldo de Menezes Martins, Akira Homma, Luiz Cosme Cota Malaquias, Pedro Luiz Tauil, Pedro Fernando Costa Vasconcelos, Alessandro Pecego Martins Romano, Carla Magda Domingues, Andréa Teixeira-Carvalho, Olindo Assis Martins-FilhoComments to Author , and Collaborative Group for Studies of Yellow Fever Vaccine
Author affiliations: Instituto René Rachou of Fundação Oswaldo Cruz (FIOCRUZ-Minas),; Belo Horizonte, Brazil (A.C. Campi-Azevedo, V. Peruhype-Magalhāes, J.G. Coelho-dos-Reis, L.R. Antonelli, C. Costa-Pereira, E. Speziali, L.R. Reis, A. Teixeira-Carvalho, O.A. Martins-Filho); Universidade Federal de Minas Gerais, Belo Horizonte (J.G. Coelho-dos-Reis); Secretaria Municipal de Saúde, Belo Horizonte (J.A. Lemos); Secretaria do Estado de Saúde de Minas Gerais, Belo Horizonte (J.G.L. Ribeiro); Escola Nacional de Saúde Pública (FIOCRUZ-Rio), Rio de Janeiro, Brazil (L.A.B. Camacho); Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos (FIOCRUZ-Rio),; Rio de Janeiro (M. de Lourdes de Sousa Maia, S.M. Barbosa de Lima, M. Simões, R. de Menezes Martins, A. Homma); Universidade Federal de Alfenas, Alfenas, Brazil (L.C.C. Malaquias); Universidade de Brasília, Brasília, Brazil (P.L. Tauil); Instituto Evandro Chagas, Ananindeua, Brazil (P.F.C. Vasconcelos); Secretaria de Vigilância em Saúde—Ministério da Saúde, Brasília (A.P.M. Romano, C.M. Domingues)

Main Article

Figure 2

Neutralizing antibody levels and seropositivity rates before and after primary and secondary 17DD vaccination for YF. We detected 17DD-specific neutralizing antibodies by micro plaque-reducing neutralization test (micro-PRNT50) and determined seropositivity rates by considering serum dilution >1:50 as the cutoff criterion for PRNT positivity. A) Scatter graph of PRNT titers, expressed as reverse of serum dilution. B) Percentage of PRNT seropositivity (serum dilution >1:50). Gray dashed lin

Figure 2. Neutralizing antibody levels and seropositivity rates before and after primary and secondary 17DD vaccination for YF. We detected 17DD-specific neutralizing antibodies by micro plaque-reducing neutralization test (micro-PRNT50) and determined seropositivity rates by considering serum dilution >1:50 as the cutoff criterion for PRNT positivity. A) Scatter graph of PRNT titers, expressed as reverse of serum dilution. B) Percentage of PRNT seropositivity (serum dilution >1:50). Gray dashed lines indicate critical seropositivity rates <80%. Participant subgroups indicate number of days or years since vaccination (in parentheses; d0 for those never vaccinated). #PV, had primary vaccination >10 years previously; NV, not vaccinated; PV, had primary vaccination only; RV, revaccinated; YF, yellow fever..

Main Article

Page created: July 16, 2019
Page updated: July 16, 2019
Page reviewed: July 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external